Abstract P352: Associations Between Signs and Symptoms of Androgen Excess With Chronic Kidney Disease in Hispanic/Latina Women of Reproductive Age in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)
Background: Androgen excess among women is characterized by high levels of testosterone and is a feature of polycystic ovary syndrome (PCOS), a common reproductive endocrine disorder in women. Evidence from animal and human studies show that androgens may promote renal dysfunction. The association between signs and symptoms of androgen excess and chronic kidney disease (CKD), however, has been relatively unexplored.
Methods: HCHS/SOL is a community-based cohort study of 16,415 self-identified Hispanic/Latino adults from diverse backgrounds in the US, including 3,801 women age 18-44 years at visit 1 (2008-2011). This preliminary cross-sectional analysis describes results from 994 reproductive-aged women who attended the ongoing visit 2 (2014-2017) by Sept. 2016. Signs and symptoms of androgen excess included menstrual cycle length (>35 days or too irregular), self-reported PCOS, and oral contraceptive use to regulate menstrual cycles or acne. We also evaluated each component separately. CKD was defined as either a low estimated glomerular filtration rate (eGFR; <60 ml/min/1.73 m2) or albuminuria based on a urine albumin/creatinine ratio ≥30 mg/g. Estimates are adjusted for sampling design, site, age, Hispanic/Latina background, education, smoking status, and body mass index.
Results: Among women reporting any sign or symptom of androgen excess (unweighted N=278), 9% reported cycles >35 days, 51% reported cycles too irregular, 49% reported oral contraceptive use to regulate cycles or acne, and 19% self-reported PCOS. Compared to women without any sign or symptom of androgen excess, women reporting a sign or symptom of androgen excess had a higher mean body mass index, waist circumference, albumin/creatinine ratio, and prevalence of hypertension and the metabolic syndrome. The prevalence of CKD (7%, 95% confidence interval (CI): 4-13%) was the same with or without signs and symptoms of androgen excess, and the association was not significant after adjusting for covariates (odds ratio (OR): 1.0; 95% CI: 0.4-2.1). When individual components were analyzed, women reporting cycles too irregular had higher odds of CKD (OR: 1.5; 95% CI: 0.6-3.7) compared to women reporting cycles of 24-35 days, although not statistically significant.
Conclusion: Over a fourth of Hispanic/Latina women reported signs and symptoms of androgen excess. Overall, there were no statistically significant associations with CKD among women reporting signs and symptoms of androgen excess. Completion of visit 2 would allow us to draw a more robust conclusion and to further characterize these relationships.
Author Disclosures: M.L. Meyer: None. D. Sotres-Alvarez: None. A. Steiner: None. L. Cousins: None. G.A. Talavera: None. J. Cai: None. M. Daviglus: None. L.R. Loehr: None.
- © 2017 by American Heart Association, Inc.